Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD

References

• GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151–1210. doi:10.1016/S0140-6736(17)32152-928919116
   PubMed Web of Science ®Google Scholar
• GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/S2213-2600(17)30293-X28822787
   PubMed Web of Science ®Google Scholar
• YinP, WangH, VosT, et al. A subnational analysis of mortality and prevalence of COPD in China from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Chest. 2016;150(6):1269–1280. doi:10.1016/j.chest.2016.08.147427693597
   PubMed Web of Science ®Google Scholar
• FangL, GaoP, BaoH, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018;6(6):421–430. doi:10.1016/S2213-2600(18)30103-629650407
   PubMed Web of Science ®Google Scholar
• WangC, XuJ, YangL, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–1717. doi:10.1016/S0140-6736(18)30841-929650248
   PubMed Web of Science ®Google Scholar
• AstraZeneca Pharmaceuticals LP. Bevespi aerosphere™ prescribing information. 2019 Available from: http://www.azpicentral.com/bevespi/bevespi_pi.pdf. Accessed 72, 2019.
   Google Scholar
• TaylorG, WarrenS, DwivediS, et al. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology. Eur J Pharm Sci. 2018;111:450–457. doi:10.1016/j.ejps.2017.10.02629055732
   PubMed Web of Science ®Google Scholar
• DotyA, SchroederJ, VangK, et al. Drug delivery from an innovative LAMA/LABA co-suspension delivery technology fixed-dose combination MDI: evidence of consistency, robustness, and reliability. AAPS PharmSciTech. 2018;19(2):837–844. doi:10.1208/s12249-017-0891-129019170
   PubMed Web of Science ®Google Scholar
• MartinezFJ, RabeKF, FergusonGT, et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. Chest. 2017;151(2):340–357. doi:10.1016/j.chest.2016.11.02827916620
   PubMed Web of Science ®Google Scholar
• HananiaNA, TashkinDP, KerwinEM, et al. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ delivery technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017;126:105–115. doi:10.1016/j.rmed.2017.03.01528427541
   PubMed Web of Science ®Google Scholar
• YasudaSU, ZhangL, HuangS-M. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008;84(3):417–423. doi:10.1038/clpt.2008.14118615002
   PubMed Web of Science ®Google Scholar
• CazzolaM, RoglianiP, SanduzziA, MateraMG. Influence of ethnicity on response to asthma drugs. Expert Opin Drug Metab Toxicol. 2015;11(7):1089–1097. doi:10.1517/17425255.2015.104734125995058
   PubMed Web of Science ®Google Scholar
• LipworthBJ, CollierDJ, GonY, et al. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA. Int J Chron Obstruct Pulmon Dis. 2018;13:2969–2984. doi:10.2147/COPD.S17185330310273
   PubMed Web of Science ®Google Scholar
• CelliBR, MacNeeW. ATS/ERS task force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946. doi:10.1183/09031936.04.0001430415219010
   PubMed Web of Science ®Google Scholar
• HankinsonJL, KawutSM, ShaharE, SmithLJ, StukovskyKH, BarrRG. Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. Chest. 2010;137(1):138–145. doi:10.1378/chest.09-091919741060
   PubMed Web of Science ®Google Scholar
• MahlerDA, WitekTJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99–103. doi:10.1081/COPD-20005066617136969
   PubMedGoogle Scholar
• JonesPW. St. George’s respiratory questionnaire: MCID. COPD. 2005;2(1):75–79. doi:10.1081/COPD-20005051317136966
   PubMedGoogle Scholar
• JonesPW, GelhornH, WilsonH, et al. Socioeconomic status as a determinant of health status treatment response in COPD trials. Chronic Obstr Pulm Dis. 2017;4(2):150–158. doi:10.15326/jcopdf.4.2.2017.013228848924
   PubMed Web of Science ®Google Scholar
• MartinezFJ, FabbriLM, FergusonGT, et al. Effect of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler (GFF MDI) delivered by novel Co-Suspension™ delivery technology on daily symptoms in patients with COPD. Am J Respir Crit Care Med. 2017;195:A5469. doi:10.1164/rccm.201701-0150WS
   Web of Science ®Google Scholar
• RabeKF, MartinezFJ, Rodriguez-RoisinR, et al. LAMA/LABA glycopyrrolate/formoterol fixed-dose combination, delivered using a novel MDI Co-Suspension™ delivery technology reduces risk of clinically important deteriorations in COPD versus placebo and monocomponent MDIs. Am J Respir Crit Care Med. 2017;195:A3594. doi:10.1164/rccm.201701-0150WS
   Web of Science ®Google Scholar
• SinghD, Maleki-YazdiMR, TombsL, IqbalA, FahyWA, NayaI. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413–1424. doi:10.2147/COPD.S10161227445468
   PubMed Web of Science ®Google Scholar
• SinghD, D’UrzoAD, ChuecosF, MuñozA, Garcia GilE. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Respir Res. 2017;18(1):106. doi:10.1186/s12931-017-0583-028558833
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. 2018 (5 2, 2018). Available from: http://www.goldcopd.org. Accessed 1030, 2018.
   Google Scholar
• SinghD, JonesPW, BatemanED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178. doi:10.1186/1471-2466-14-17825404569
   PubMed Web of Science ®Google Scholar
• MahlerDA, KerwinE, AyersT, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(9):1068–1079. doi:10.1164/rccm.201505-1048OC26177074
   PubMed Web of Science ®Google Scholar
• BuhlR, MaltaisF, AbrahamsR, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969–979. doi:10.1183/09031936.0013601425573406
   PubMed Web of Science ®Google Scholar
• DonohueJF, Maleki-YazdiMR, KilbrideS, MehtaR, KalbergC, ChurchA. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi:10.1016/j.rmed.2013.06.00123830094
   PubMed Web of Science ®Google Scholar
• WangC, SunT, HuangY, et al. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study. Int J Chron Obstruct Pulmon Dis. 2015;10:57–68. doi:10.2147/COPD.S7265025609940
   PubMed Web of Science ®Google Scholar
• MinakataY, IijimaH, TakahashiT, et al. Efficacy and safety of formoterol in Japanese patients with COPD. Intern Med. 2008;47(4):217–223. doi:10.2169/internalmedicine.47.049418277020
   PubMed Web of Science ®Google Scholar
• FukushimaY, NakataniY, IdeY, et al. Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:1187–1194. doi:10.2147/COPD.S15924629695902
   PubMed Web of Science ®Google Scholar
• ZhengJ, ZhongN, NewlandsA, ChurchA, GohAH. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study. Int J Chron Obstruct Pulmon Dis. 2015;10:1753–1767. doi:10.2147/COPD.S8105326366068
   PubMed Web of Science ®Google Scholar
• WedzichaJA, ZhongN, IchinoseM, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. Int J Chron Obstruct Pulmon Dis. 2017;12:339–349. doi:10.2147/COPD.S12505828176893
   PubMed Web of Science ®Google Scholar
• BaiC, IchinoseM, LeeSH, et al. Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2017;12:3329–3339. doi:10.2147/COPD.S13771929200840
   PubMed Web of Science ®Google Scholar
• Bosnic-AnticevichS, ChrystynH, CostelloRW, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis. 2016;12:59–71. doi:10.2147/COPD.S11719628053517
   PubMed Web of Science ®Google Scholar
• PriceD, ChrystynH, KaplanA, et al. Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care. Allergy Asthma Immunol Res. 2012;4(4):184–191. doi:10.4168/aair.2012.4.4.18422754711
   PubMed Web of Science ®Google Scholar
• LavoriniF, CorriganCJ, BarnesPJ, et al. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med. 2011;105(7):1099–1103. doi:10.1016/j.rmed.2011.03.01221489771
   PubMed Web of Science ®Google Scholar
• MahlerDA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14(7):1103–1107. doi:10.1513/AnnalsATS.201702-156PS28481631
   PubMed Web of Science ®Google Scholar
• FakihF, SpangenthalS, SigalB, et al. Randomized study of the effects of Aerochamber Plus® Flow-Vu® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease. Respir Med. 2018;138:74–80. doi:10.1016/j.rmed.2018.03.03329724397
   PubMed Web of Science ®Google Scholar
• LavoriniF, FontanaGA. Targeting drugs to the airways: the role of spacer devices. Expert Opin Drug Deliv. 2009;6(1):91–102. doi:10.1517/1742524080263786219236210
   PubMed Web of Science ®Google Scholar
• BattistiWP, WagerE, BaltzerL, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163(6):461–464. doi:10.7326/M15-028826259067
   PubMed Web of Science ®Google Scholar